CBCC Global Research

Executive Summary

CBCC Global Research, rebranding as REV Clinical, is a full-service clinical research organization (CRO) headquartered in the US with primary operations in India. Founded in 2010, the company provides comprehensive Phase I-IV trial services, regulatory support, biometrics, and medical writing to pharmaceutical and medical device companies. Its therapeutic focus spans oncology, ophthalmology, neuro-psychiatry, rare diseases, and dermatology, positioning it to capitalize on growing demand for specialized CRO services. Leveraging India’s cost advantages and a skilled workforce, CBCC offers competitive pricing and efficient trial conduct, attracting mid-to-large pharma sponsors. The rebranding to REV Clinical aims to modernize its identity and expand global reach. As a private entity, CBCC is well-positioned to navigate market shifts with agility, though it faces intense competition from larger global CROs. Future growth is expected from its established presence in high-growth therapeutic areas and potential expansions into emerging markets.

Upcoming Catalysts (preview)

• Q3 2026Rebranding to REV Clinical Completed90% success
• Q4 2026Securing Major Oncology Trial Contracts50% success
• Q2 2027Expansion into Rare Disease Clinical Services40% success